Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy - a Phase II Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Sponsor: Novartis Pharmaceuticals
Terminated
Primary endpoint reached futility boundary
Other terminated trials from Novartis Pharmaceuticals
Other Head and Neck Cancer trials with similar outcome
Listed as NCT01133678, this PHASE2 trial focuses on Head and Neck Cancer and remains terminated or withdrawn. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Nov 2019 — Jun 2020 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .